Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice.

ABSTRACT:

Background

Twenty years after the onset of diabetes, up to 40% of patients develop diabetic nephropathy. Protease-activated receptor-1 (PAR-1) has recently been shown to aggravate the development of experimental diabetic nephropathy. PAR-1 deficient mice develop less albuminuria and glomerular lesions and PAR-1 stimulation induces proliferation and fibronectin production in mesangial cells in vitro. Vorapaxar is a clinically available PAR-1 inhibitor which is currently used for secondary prevention of ischemic events.

Objectives

The aim of this study was to investigate in a preclinical setting whether vorapaxar treatment may be a novel strategy to reduce diabetes-induced kidney damage.

Results

While control treated diabetic mice developed significant albuminuri

SUBMITTER: Waasdorp M 

PROVIDER: S-EPMC5955164 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature